ArticleFrontiers in radiology2026
Imaging and procedural features of staged bilateral magnetic resonance-guided focused ultrasound thalamotomy for essential tremor.
Article in Frontiers in radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Magnetic Resonance-guided Focused Ultrasound (MRgFUS) thalamotomy is an established incisionless treatment for medication-refractory essential tremor (ET). While staged-bilateral MRgFUS thalamotomy has recently gained clinical acceptance, detailed radiological and procedural comparisons between first- and second-side interventions remain limited. This study aimed to provide a comprehensive imaging-based and procedural characterisation of staged bilateral MRgFUS thalamotomy, with a specific focus on stereotactic targeting, sonication parameters, and lesion morphology. Materials and methods: In this retrospective-prospective, single-centre observational study, consecutive patients with ET undergoing staged bilateral MRgFUS thalamotomy were included. Procedural metrics, stereotactic targeting coordinates, and sonication parameters were compared between FUS1 and FUS2 procedures. MRI analyses were performed using a standardised protocol including morphological pre-treatment 3D T1-weighted imaging and post-treatment 3D T2-weighted imaging acquired within 24 h and at approximately 1 month to document the lesion. Treatment-related lesions were segmented using a semi-automated approach, with volumetric measurements independently obtained by two blinded raters; inter-rater agreement was assessed using intraclass correlation coefficients. Adverse events (AEs) were recorded as secondary outcomes. A systematic review of the literature on treatment strategy of staged bilateral MRgFUS thalamotomy was conducted. Results: Fifteen patients underwent staged bilateral MRgFUS thalamotomy. Most anatomical, procedural, and sonication-related parameters were comparable between FUS1 and FUS2. Final stereotactic targeting during FUS2 showed a small but consistent anterior and dorsal shift relative to FUS1. Lesion volumes measured at both 24 h and 1 month after the procedure did not differ significantly between FUS1 and FUS2, and inter-rater agreement for lesion volumetry was excellent across time points (ICC > 0.91). AEs after FUS2 were predominantly mild and transient. We found no significant differences in lesion volume or inter-side targeting displacement between patients with and without gait disturbances, the most common AE, persisting at 1 month after FUS2. Single-patient imaging analyses suggested heterogeneous spatial lesion configurations in patients with AEs persistent 6-12 months after FUS2. Conclusion: In this single-centre cohort, staged bilateral MRgFUS thalamotomy showed high procedural and radiological consistency between FUS1 and FUS2. MRI-based volumetric analyses show consistent lesion morphology across hemispheres, with small, safety-oriented refinements in second-side targeting, in line with the literature.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.